Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. The company is headquartered in Indianapolis, Indiana and currently employs 9,400 full-time employees. The company went IPO on 2018-09-20. The firm is engaged in delivering products and services to prevent and treat disease in farm animals and pets. The company serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. The company includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. The company offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. The company offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep.
最新の財務諸表(Form-10K)によると、Elanco Animal Health Incの総資産は$0で、純損失は$0です。
ELANの主要な財務比率は何ですか?
Elanco Animal Health Incの流動比率は0、純利益率は0、1株当たり売上高は$0です。
Elanco Animal Health Incの収益はセグメントまたは地域別にどのように分けられていますか?
Elanco Animal Health Inc の最大収益セグメントは Pet Health で、最新の利益発表における収益は 2,300,000,000 です。地域別に見ると、United States が Elanco Animal Health Inc の主要市場であり、収益は 2,234,000,000 です。
Elanco Animal Health Incは収益を上げていますか?
いいえ、最新の財務諸表によると、Elanco Animal Health Incの純損失は$0です。